Skip to Main Content

Paper Details

Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Nat Rev Clin Oncol
16
2023
EGFR, EGFR variant III, EGFR-amplified glioblastoma, HER2, HER2 breast cancer, Primary and secondary brain tumours, brain metastases, brain tumours, cancer, depatuxizumab mafodotin, gliomas, patients, primary and secondary, primary and secondary brain tumours, trastuzumab, wild-type EGFR
Author NameAffiliation
Anna S BerghoffMedical University of Vienna
Anna S BerghoffMedical University of Vienna
Priscilla K BrastianosMassachusetts General Hospital and Harvard Medical School
Priscilla K BrastianosMassachusetts General Hospital and Harvard Medical School
Nancy U LinDana-Farber Cancer Institute
Patrick Y WenBrigham and Women's Hospital and Harvard Medical School
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
Michael WellerClinical Neuroscience Center, University Hospital and University of Zurich
Matthias PreusserMedical University of Vienna
Matthias PreusserMedical University of Vienna
Matthias PreusserMedical University of Vienna
Matthias PreusserMedical University of Vienna
  • 1 - 12

Datasets

Release 1.2